Ivermectin development roadmap

As malaria transmission is curbed by effective vector control with indoor tools (LLINs and IRS), drug-based strategies and economic development, the relative importance of residual transmission increases. This poses a serious threat to reaching elimination goals.

Mass administration of ivermectin (a drug capable of targeting malaria vectors regardless of time and place of biting) has gained increased attention by funders, academia and international organizations as a potential complementary tool for malaria elimination. There is now clear WHO guidance on the Preferred Product Characteristics for such a tool and a draft Target Candidate Profile by Medicines for Malaria Venture.  Still, the malaria community lacks alignment on the processes needed to transform the potential of ivermectin into an implemented tool. This project aims to produce a roadmap for such transformation including key issues to be resolved (dose, regimen, eligibility, regulatory pathway), go/no-go criteria along the evaluation and development process. For this, the ivermectin taskforce, a group of experts and stakeholders, will work on complementary streams to produce a roadmap document and accompanying TPPs that can guide related investments and efforts.

Bill & Melinda Gates Foundation, Grants

Health Systems & Op. Research
Product Development
Vector Control

Aug 2017 — Aug 2018

$99,985

Spain

Ivermectin for malaria